Half of Patients With Psoriasis Receiving Placebo In Clinical Trials Report Adverse Events
A recent review and meta-analysis says this statistic may be due in part to nocebo effects.
Rates, Incidence of Skin Cancer Found to be Higher in Patients With Skin of Color and in Rural Communities
Two posters at the AAD Annual Meeting examined disparities in skin cancer survival between urban and rural areas and assessed how having skin of color affects this.
PF-07038124 Demonstrates Superior Efficacy in Mild to Moderate Atopic Dermatitis, Plaque Psoriasis
The topical therapy was more effective in patients with psoriasis and AD when compared to a vehicle control cream.
More Images of Patients With Psoriasis Are Needed in Published Studies
Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.
No Significant Difference in BMI, Weight Regarding Switching Rates for Patients with Psoriasis
Label warnings may affect the initiation of new treatment and real-world switching patterns for psoriasis patients starting treatment with risankizumab.
Tildrakizumab Significantly Improved Work Productivity and More in Patients With Plaque Psoriasis
In addition to improvements in work productivity, tildrakizumab also demonstrated significant efficacy and safety.
Patients With Mild Psoriasis Experience Less Favorable Status at Diagnosis and First Line of Treatment
Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.
Palmoplantar Psoriasis Risk Increased Among Black and Male Patients
Black and male patients exhibited a higher prevalence of palmoplantar psoriasis when compared with White patients.
Severe Psoriasis Associated With Higher Risk of Heart Disease
Researchers explored the relationship between psoriasis severity and its link to coronary microvascular dysfunction in the largest such study to date.
Race, Access to Psoriasis Biologics Not Independently Associated
Researchers noted a lack of significant differences in access to biologics among different populations.